Table 4. Logistic regression analysis for the odds of febrile neutropenia among patients with primary prophylactic pegfilgrastim (n = 132).
| Variable | OR | 95% CI | p-value | |
|---|---|---|---|---|
| Age | 0.842 | |||
| < 60 years | 1 | |||
| ≥ 60 years | 1.10 | 0.45–2.68 | ||
| BMI (kg/m2) | 0.130 | |||
| Normal (18.5–24.9) | 1 | |||
| Overweight (> 25.0) | 1.79 | 0.84–3.81 | ||
| Menopausal status | 0.519 | |||
| Premenopausal | 1 | |||
| postmenopausal | 1.30 | 0.60–2.79 | ||
| Pathologic T stage | 0.215 | |||
| T1 | 1 | |||
| T2 | 0.92 | 0.42–1.98 | ||
| T3–T4 | 7.33 | 0.71–75.27 | ||
| Pathologic N stage | 0.582 | |||
| N1 | 1 | |||
| More than N2 | 1.27 | 0.54–2.95 | ||
| Histologic grade | 0.406 | |||
| G1, G2 | 1 | |||
| G3 | 1.37 | 0.65–2.92 | ||
| Histologic type | 0.372 | |||
| Invasive ductal | 1 | |||
| Invasive lobular | 0.43 | 0.05–3.83 | ||
| Others | 0.27 | 0.03–2.24 | ||
| Hormone receptor | 0.741 | |||
| ER and/or PR positive | 1 | |||
| ER and PR negative | 0.86 | 0.36–2.08 | ||
| HER2 | 0.741 | |||
| Negative | 1 | |||
| Positive | 0.86 | 0.36–2.08 | ||
| Co-morbidity | 0.992 | |||
| No | 1 | |||
| Diabetes | 1.06 | 0.26–4.38 | ||
| Hypertension | 1.14 | 0.39–3.29 | ||
| Diabetes + Hypertension | 1.23 | 0.21–7.11 | ||
| Smoking | 0.974 | |||
| No | 1 | |||
| Yes | 1.02 | 0.25–4.18 | ||
BMI = body mass index; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; OR = odds ratio; CI = confidence interval.